
- Industry news
Industry news
- Category news
Category news
- Reports
- Key trends
- Multimedia
Multimedia
- Journal
- Events
- Suppliers
- Home
- Industry news
Industry news
- Category news
Category news
- Reports
- Key trends
- Multimedia
Multimedia
- Events
- Suppliers
IFT FIRST 2026 review: GLP-1 ripple effect reshapes functional food innovation
The influence of GLP-1 medications extends far beyond the products marketed to users. IFT FIRST 2026 in Chicago, US, last week, suggested a more consequential story: how GLP-1 weight management drugs are accelerating established demands for nutrient density, satiety, sustained energy, and digestive support in everyday F&B. Rather than creating one uniform “GLP-1 consumer,” the trend is fragmenting the market into different nutritional and sensory needs. GLP-1 medications are incentivizing product developers to become more precise about the nutritional outcomes of their F&B solutions.Puris CEO Tyler Lorenzen discusses the company’s latest pea protein launch and how it addresses common formulation challenges at IFT FIRST 2026. He explains why high-protein ingredients are moving beyond sports nutrition into mainstream F&B, and why low viscosity, smooth texture, clean taste, and clean labels are critical as plant-based protein expands into everyday categories.
Settings
- Play Interval
- Slide Duration
- Thumbnail Bar Position
Latest headlines

Color innovation breakthroughs Jul 2026

F&B flavor trends in focusJul 2026
Multimedia
Puris CEO Tyler Lorenzen discusses the company’s latest pea protein launch and how it addresses common formulation challenges at IFT FIRST 2026. He explains why high-protein ingredients are moving beyond sports nutrition into mainstream F&B, and why low viscosity, smooth texture, clean...



























